{"id":8516,"date":"2025-09-05T19:40:21","date_gmt":"2025-09-05T16:40:21","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8516"},"modified":"2025-09-05T19:40:21","modified_gmt":"2025-09-05T16:40:21","slug":"baxhtn-trial-baxdrostat-in-resistant-uncontrolled-hypertension","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/baxhtn-trial-baxdrostat-in-resistant-uncontrolled-hypertension\/","title":{"rendered":"BaxHTN Trial \u2013 Baxdrostat in Resistant\/Uncontrolled Hypertension"},"content":{"rendered":"<div>BaxHTN Trial \u2013 Baxdrostat in Resistant\/Uncontrolled Hypertension<\/div>\n<div><\/div>\n<div>Source: Medical News | ESC 2025 | August 31, 2025<\/div>\n<div><\/div>\n<div><span> 1. Background<\/span><\/div>\n<div><span> \u2022 Baxdrostat: first-in-class aldosterone synthase inhibitor.<\/span><\/div>\n<div><span> \u2022 Targets overproduction of aldosterone \u2192 key driver of resistant\/uncontrolled hypertension.<\/span><\/div>\n<div><span> 2. Design<\/span><\/div>\n<div><span> \u2022 Phase 3 RCT, 794 patients with resistant (73%) or uncontrolled (27%) hypertension.<\/span><\/div>\n<div><span> \u2022 Already on \u22653 antihypertensives (99% diuretic, 90% ACEi\/ARB).<\/span><\/div>\n<div><span> \u2022 Randomized to baxdrostat (1 mg or 2 mg daily) vs placebo for 12 weeks.<\/span><\/div>\n<div><span> 3. Results<\/span><\/div>\n<div><span> \u2022 Office SBP reduction (placebo-corrected):<\/span><\/div>\n<div><span> \u2022 \u20138.7 mmHg (1 mg)<\/span><\/div>\n<div><span> \u2022 \u20139.8 mmHg (2 mg)<\/span><\/div>\n<div><span> \u2022 24h Ambulatory SBP reduction: \u2248 \u201315 mmHg.<\/span><\/div>\n<div><span> \u2022 Nighttime SBP reduction: \u201312 mmHg.<\/span><\/div>\n<div><span> \u2022 Effect persisted after withdrawal phase (minimal rebound).<\/span><\/div>\n<div><span> 4. Safety<\/span><\/div>\n<div><span> \u2022 Generally well tolerated.<\/span><\/div>\n<div><span> \u2022 Hyperkalemia risk:<\/span><\/div>\n<div><span> \u2022 K\u207a &gt;6 mmol\/L in 2.3\u20133%.<\/span><\/div>\n<div><span> \u2022 Required intervention in 2.7% (1 mg) and 7.9% (2 mg).<\/span><\/div>\n<div><span> \u2022 Monitoring of potassium recommended at initiation.<\/span><\/div>\n<div><span> 5. Interpretation<\/span><\/div>\n<div><span> \u2022 Baxdrostat shows robust BP lowering on top of intensive therapy.<\/span><\/div>\n<div><span> \u2022 Durable effect suggests potential to reset disease mechanisms (aldosterone-driven sodium retention, vascular stiffening).<\/span><\/div>\n<div><span> \u2022 Experts called it a \u201cgame changer\u201d for resistant hypertension.<\/span><\/div>\n<div><span> 6. Funding<\/span><\/div>\n<div><span> \u2022 Trial funded by AstraZeneca.<\/span><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/www.medscape.com\/viewarticle\/baxdrostat%E2%80%91game%E2%80%91changer%E2%80%91hypertension%E2%80%912025a1000mz7\">\u00a0www.medscape.com\/viewarticle\/baxdrostat\u2011game\u2011changer\u2011hypertension\u20112025a1000mz7<\/a><\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BaxHTN Trial \u2013 Baxdrostat in Resistant\/Uncontrolled Hypertension Source: Medical News | ESC 2025 | August 31, 2025 1. Background \u2022 Baxdrostat: first-in-class aldosterone synthase inhibitor. \u2022 Targets overproduction of aldosterone \u2192 key driver of resistant\/uncontrolled hypertension. 2. Design \u2022 Phase 3 RCT, 794 patients with resistant (73%) or uncontrolled (27%) hypertension. \u2022 Already on \u22653 [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8516","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8516"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8516\/revisions"}],"predecessor-version":[{"id":8518,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8516\/revisions\/8518"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}